Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp, Warren Mason, Martin J. van den Bent, +16

New England Journal of Medicine

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp, Monika E. Hegi, Warren Mason, +21

The Lancet Oncology

5-Year AnalysisNeuro-oncologyOncologyRadiation TherapyAdjuvant Temozolomide +6

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran, +188

The Lancet Oncology

Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3 +8

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

Thierry Gorlia, Martin J. van den Bent, Monika E. Hegi, +9

The Lancet Oncology

Neuro-oncologyPrognostic BiomarkersGliomaNcic TrialPrognostic Factor Analysis +6

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Bertrand Routy, John Lenehan, Wilson H. Miller, +34

Nature Medicine

Tumor ImmunologyAnti-pd-1 ImmunotherapyCancer ImmunosurveillanceMedicineMelanoma +10

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

James Perry, Karl Bélanger, Warren Mason, +10

Journal of Clinical Oncology

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

Arielle Elkrief, Layal El Raichani, Corentin Richard, +9

OncoImmunology

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

Brian Thiessen, Clinton F. Stewart, Ming‐Sound Tsao, +8

Cancer Chemotherapy and Pharmacology

OncologyMolecular CorrelationMedicinePathologyClinical Outcomes +8

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Teresa M. Petrella, Richard Tozer, Karl Bélanger, +10

Journal of Clinical Oncology

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

D. Scott Ernst, Elizabeth A. Eisenhauer, Nancy Wainman, +5

Investigational New Drugs

Surgical OncologyMedicineMelanomaPhase Ii StudyMetastatic Melanoma +4